Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion

Gábor János Szebeni, Éva Kriston-Pál, Péter Blazsó, R. Katona, Julianna Novák, Eniko Szabó, A. Czibula, R. Fajka-Boja, Beáta Hegyi, F. Uher, L. Krenács, Gabriella Joó, E. Monostori

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Bone marrow derived mesenchymal stromal cells (MSCs) have recently been implicated as one source of the tumor-associated stroma, which plays essential role in regulating tumor progression. In spite of the intensive research, the individual factors in MSCs controlling tumor progression have not been adequately defined. In the present study we have examined the role of galectin-1 (Gal-1), a protein highly expressed in tumors with poor prognosis, in MSCs in the course of tumor development. Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells enhances the incidence of palpable tumors, growth, vascularization and metastasis. It also reduces survival compared to animals treated with tumor cells alone or in combination with Gal-1 knockout MSCs. In vitro studies show that the absence of Gal-1 in MSCs does not affect the number of migrating MSCs toward the tumor cells, which is supported by the in vivo migration of intravenously injected MSCs into the tumor. Moreover, differentiation of endothelial cells into blood vessel-like structures strongly depends on the expression of Gal-1 in MSCs. Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By administering B16F10 melanoma cells into Gal-1 deficient animals, tumor growth is highly reduced compared to wild type animals. Nevertheless, co-injection of wild type but not Gal-1 deficient MSCs results in dramatic tumor growth and development. These results confirm that galectin-1 is one of the critical factors in MSCs regulating tumor progression.

Original languageEnglish
Article numbere41372
JournalPLoS One
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 23 2012

Fingerprint

Galectin 1
stromal cells
Mesenchymal Stromal Cells
Tumors
neoplasms
mice
Neoplasms
Animals
Cells
animals
Wild Animals
Endothelial cells
Blood vessels
melanoma
Growth
Growth and Development
blood vessels
Knockout Mice
metastasis
in vitro studies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion. / Szebeni, Gábor János; Kriston-Pál, Éva; Blazsó, Péter; Katona, R.; Novák, Julianna; Szabó, Eniko; Czibula, A.; Fajka-Boja, R.; Hegyi, Beáta; Uher, F.; Krenács, L.; Joó, Gabriella; Monostori, E.

In: PLoS One, Vol. 7, No. 7, e41372, 23.07.2012.

Research output: Contribution to journalArticle

Szebeni, Gábor János ; Kriston-Pál, Éva ; Blazsó, Péter ; Katona, R. ; Novák, Julianna ; Szabó, Eniko ; Czibula, A. ; Fajka-Boja, R. ; Hegyi, Beáta ; Uher, F. ; Krenács, L. ; Joó, Gabriella ; Monostori, E. / Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion. In: PLoS One. 2012 ; Vol. 7, No. 7.
@article{55dde9a3ffdb4a93b9ff45fddc10a48f,
title = "Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion",
abstract = "Bone marrow derived mesenchymal stromal cells (MSCs) have recently been implicated as one source of the tumor-associated stroma, which plays essential role in regulating tumor progression. In spite of the intensive research, the individual factors in MSCs controlling tumor progression have not been adequately defined. In the present study we have examined the role of galectin-1 (Gal-1), a protein highly expressed in tumors with poor prognosis, in MSCs in the course of tumor development. Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells enhances the incidence of palpable tumors, growth, vascularization and metastasis. It also reduces survival compared to animals treated with tumor cells alone or in combination with Gal-1 knockout MSCs. In vitro studies show that the absence of Gal-1 in MSCs does not affect the number of migrating MSCs toward the tumor cells, which is supported by the in vivo migration of intravenously injected MSCs into the tumor. Moreover, differentiation of endothelial cells into blood vessel-like structures strongly depends on the expression of Gal-1 in MSCs. Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By administering B16F10 melanoma cells into Gal-1 deficient animals, tumor growth is highly reduced compared to wild type animals. Nevertheless, co-injection of wild type but not Gal-1 deficient MSCs results in dramatic tumor growth and development. These results confirm that galectin-1 is one of the critical factors in MSCs regulating tumor progression.",
author = "Szebeni, {G{\'a}bor J{\'a}nos} and {\'E}va Kriston-P{\'a}l and P{\'e}ter Blazs{\'o} and R. Katona and Julianna Nov{\'a}k and Eniko Szab{\'o} and A. Czibula and R. Fajka-Boja and Be{\'a}ta Hegyi and F. Uher and L. Kren{\'a}cs and Gabriella Jo{\'o} and E. Monostori",
year = "2012",
month = "7",
day = "23",
doi = "10.1371/journal.pone.0041372",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Identification of galectin-1 as a critical factor in function of mouse mesenchymal stromal cell-mediated tumor promotion

AU - Szebeni, Gábor János

AU - Kriston-Pál, Éva

AU - Blazsó, Péter

AU - Katona, R.

AU - Novák, Julianna

AU - Szabó, Eniko

AU - Czibula, A.

AU - Fajka-Boja, R.

AU - Hegyi, Beáta

AU - Uher, F.

AU - Krenács, L.

AU - Joó, Gabriella

AU - Monostori, E.

PY - 2012/7/23

Y1 - 2012/7/23

N2 - Bone marrow derived mesenchymal stromal cells (MSCs) have recently been implicated as one source of the tumor-associated stroma, which plays essential role in regulating tumor progression. In spite of the intensive research, the individual factors in MSCs controlling tumor progression have not been adequately defined. In the present study we have examined the role of galectin-1 (Gal-1), a protein highly expressed in tumors with poor prognosis, in MSCs in the course of tumor development. Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells enhances the incidence of palpable tumors, growth, vascularization and metastasis. It also reduces survival compared to animals treated with tumor cells alone or in combination with Gal-1 knockout MSCs. In vitro studies show that the absence of Gal-1 in MSCs does not affect the number of migrating MSCs toward the tumor cells, which is supported by the in vivo migration of intravenously injected MSCs into the tumor. Moreover, differentiation of endothelial cells into blood vessel-like structures strongly depends on the expression of Gal-1 in MSCs. Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By administering B16F10 melanoma cells into Gal-1 deficient animals, tumor growth is highly reduced compared to wild type animals. Nevertheless, co-injection of wild type but not Gal-1 deficient MSCs results in dramatic tumor growth and development. These results confirm that galectin-1 is one of the critical factors in MSCs regulating tumor progression.

AB - Bone marrow derived mesenchymal stromal cells (MSCs) have recently been implicated as one source of the tumor-associated stroma, which plays essential role in regulating tumor progression. In spite of the intensive research, the individual factors in MSCs controlling tumor progression have not been adequately defined. In the present study we have examined the role of galectin-1 (Gal-1), a protein highly expressed in tumors with poor prognosis, in MSCs in the course of tumor development. Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells enhances the incidence of palpable tumors, growth, vascularization and metastasis. It also reduces survival compared to animals treated with tumor cells alone or in combination with Gal-1 knockout MSCs. In vitro studies show that the absence of Gal-1 in MSCs does not affect the number of migrating MSCs toward the tumor cells, which is supported by the in vivo migration of intravenously injected MSCs into the tumor. Moreover, differentiation of endothelial cells into blood vessel-like structures strongly depends on the expression of Gal-1 in MSCs. Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By administering B16F10 melanoma cells into Gal-1 deficient animals, tumor growth is highly reduced compared to wild type animals. Nevertheless, co-injection of wild type but not Gal-1 deficient MSCs results in dramatic tumor growth and development. These results confirm that galectin-1 is one of the critical factors in MSCs regulating tumor progression.

UR - http://www.scopus.com/inward/record.url?scp=84864184167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864184167&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0041372

DO - 10.1371/journal.pone.0041372

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e41372

ER -